Harmony Biosciences (HRMY) | Stock Overview & Key Data
Harmony Biosciences Performance Comparison
Stock Range
Today's Range
Low: $33.71
High: $34.66
on August 8, 2025
52 Week Range
Low: $26.47
High: $41.61
on April 9, 2025
on October 29, 2024
All-Time High: $62.08 on December 5, 2022
Explore how other US stocks compare to their 52-week ranges: View US Market 52-Week Insights
Key Statistics
Market Cap
$2.0B
EPS
2.62
P/E Ratio (TTM)
13.13
Forward P/E
10.56
P/B Ratio
2.74
PEG Ratio
10.56
Div. Yield
N/A
ROE
24.71%
Beta
0.839
Debt to Equity
24.63
Financial Highlights
Profitability
Gross Margin
82.68%
Operating Margin
30.45%
Profit Margin
20.50%
Returns and Earnings
Return on Assets (TTM)
12.81%
Return on Equity (TTM)
24.71%
EBITDA
$237.9M
Net Income (TTM)
$152.7M
Growth
Revenue (TTM)
Revenue Per Share (TTM)
$13.03
Quarterly Revenue Growth (YoY)
19.50%
Quarterly Earnings Growth (YoY)
18.90%
Peer Performance Comparison
| Company | Market Cap | 1W | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y |
|---|---|---|---|---|---|---|---|---|---|
| Harmony Biosciences HRMY | 1.98B Small-cap | -2.79% | 6.08% | 2.27% | -8.68% | -1.81% | 2.45% | -33.52% | -3.69% |
| Vertex VRTX | 121.28B Large-cap | -17.78% | -18.24% | -13.61% | -19.96% | -7.43% | -17.68% | 30.94% | 44.28% |
| Regeneron REGN | 60.39B Large-cap | 2.63% | 4.03% | -0.20% | -21.15% | -21.73% | -50.93% | -11.70% | -9.38% |
| Ocular Therapeutix OCUL | 1.97B Small-cap | 6.22% | 27.99% | 74.47% | 62.48% | 40.73% | 49.88% | 128.10% | 56.45% |
| Beam Therapeutics BEAM | 1.85B Small-cap | -9.39% | -6.88% | 10.04% | -34.84% | -27.69% | -26.98% | -74.15% | -20.55% |
| Vericel VCEL | 1.85B Small-cap | 3.46% | -8.27% | -10.67% | -38.05% | -34.40% | -20.42% | 29.01% | 136.42% |
Ownership & Short Interest
Insider Ownership
11.10%
Institutional Ownership
93.12%
Shares Short
4M
Short Ratio
7.33
Short % of Shares Outstanding
16.99%
Average 10-Day Volume
546K
Average 90-Day Volume
597K
Harmony Biosciences Recurring Investment / Dollar-Cost Averaging Calculator
Calculate how a regular investment in Harmony Biosciences would have performed over time.
Note: This calculator is for informational purposes only and does not consider taxes, fees, or other costs associated with investing.
Frequently Asked Questions
- What is HRMY's 52-week high and low?
- In the last 52 weeks, Harmony Biosciences reached a high of $41.61 (on October 29, 2024) and a low of $26.47 (on April 9, 2025).
- What is the market cap and P/E ratio for HRMY?
- Curious about Harmony Biosciences's size and valuation? Its market capitalization stands at 1.98B. When it comes to valuation, the P/E ratio (trailing twelve months) is 13.13, and the forward P/E (looking ahead) is 10.56.
- Does HRMY pay dividends? If so, what's the yield?
- As for dividends, Harmony Biosciences isn't currently offering a significant yield, or that specific data isn't available right now.
- Who are Harmony Biosciences's main competitors or similar companies to consider before investing?
When looking at Harmony Biosciences, it can be helpful to see how it compares to other players in its field. Here are a few similar companies or key competitors:
Company Mkt Cap Sector Industry 1Y Return 3Y Return Vertex
VRTX121.28B Healthcare Biotechnology -17.68% 30.94% Regeneron
REGN60.39B Healthcare Biotechnology -50.93% -11.70% Ocular Therapeutix
OCUL1.97B Healthcare Biotechnology 49.88% 128.10% Beam Therapeutics
BEAM1.85B Healthcare Biotechnology -26.98% -74.15% Vericel
VCEL1.85B Healthcare Biotechnology -20.42% 29.01% For a more comprehensive list, please see the Peer Performance Comparison table on this page.
- What are the key financial health indicators for Harmony Biosciences Holdings, Inc.? (e.g., ROE, Debt/Equity)
- To get a sense of Harmony Biosciences's financial health, here are a few key indicators: its Return on Equity (ROE) over the last twelve months is 24.71%, the Debt to Equity ratio from the most recent quarter is 24.63, and its Gross Profit Margin stands at 82.68%.
- What is the recent revenue and earnings growth for HRMY?
- Looking at Harmony Biosciences's growth, its revenue over the trailing twelve months (TTM) was $745M. Compared to the same quarter last year (YoY), quarterly revenue grew by 19.50%, and quarterly earnings saw a YoY growth of 18.90%.
- How much of HRMY stock is held by insiders and institutions?
- Wondering who owns Harmony Biosciences stock? Company insiders (like executives and directors) hold about 11.10% of the shares, while institutional investors (such as mutual funds and pension funds) own approximately 93.12%.
For more common questions about our data, please visit our About Data page.
Data is provided for informational purposes only. Devyara does not guarantee the accuracy of the data displayed.